Submit Manuscript  

Article Details

Privileged Pharmacophore of FDA Approved Drugs in Combination with Chalcone Framework: A New Hope for Alzheimer’s Treatment

[ Vol. 23 , Issue. 9 ]


Bijo Mathew*   Pages 842 - 846 ( 5 )


Multi-functional design of ligands emerged as a new drug design paradigm of Alzheimer’s disease (AD). Given the complexity of AD, the molecules showing dual inhibition of monoamine oxidase (MAO) and acetylcholinesterase (AChE) with neuroprotective properties could prevent the progressive neural degeneration effectively. Numerous studies documented that chalcone is a privileged structural framework for the inhibition of both MAO and AChE. The recent studies suggested that the development of chalcone candidates endowed with pharmacophores of FDA approved drugs may become an active molecules in the field of current AD research. The current perspective described the recent updates of chalcone moiety linked with the pharmacophores of flurbiprofen and rivastigmine hybrids as selective ChE/MAO-B inhibitors for the prophylactic agents for AD.


Chalcones, pharmacophore, monoamine oxidase, acetylcholinesterase, flurbiprofen, rivastigmine.


Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, Amrita Health Science Campus, Kochi-682 041

Read Full-Text article